Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Universe Pharmaceuticals Inc (UPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: UPC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.17% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.06M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.51 | 52 Weeks Range 2.51 - 2592.00 | Updated Date 06/29/2025 |
52 Weeks Range 2.51 - 2592.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -639.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.9% | Operating Margin (TTM) -61.93% |
Management Effectiveness
Return on Assets (TTM) -9.14% | Return on Equity (TTM) -23.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -19447324 | Price to Sales(TTM) 0.09 |
Enterprise Value -19447324 | Price to Sales(TTM) 0.09 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 563338 | Shares Floating 42879 |
Shares Outstanding 563338 | Shares Floating 42879 | ||
Percent Insiders 0.61 | Percent Institutions 0.05 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Universe Pharmaceuticals Inc
Company Overview
History and Background
Universe Pharmaceuticals Inc. was founded in 2004 and is based in China. They are involved in the research, development, manufacturing, marketing, and distribution of traditional Chinese medicine (TCM) products in China.
Core Business Areas
- TCM Products: Focused on the manufacture and sale of TCM products, primarily for digestive health, cardiovascular health, and general well-being.
- Modern Medicine: Includes the sale of modern over-the-counter (OTC) and prescription drugs.
- Nutritional Supplements: Offer a range of nutritional supplements and health foods.
Leadership and Structure
The company is led by CEO, Haiqin Zhang and operates with a typical corporate structure involving board of directors and various departments responsible for R&D, manufacturing, marketing, and distribution.
Top Products and Market Share
Key Offerings
- Gastrointestinal TCM Products: These TCM products target digestive issues and constitute a significant portion of their revenue. Competitors include other Chinese medicine companies and multinational pharmaceutical companies with digestive health products. Market Share data is not readily available.
- Cardiovascular TCM Products: TCM products designed to promote cardiovascular health. Competitors are other TCM brands and Western medicine providers. Market Share data is not readily available.
- OTC and Prescription Drugs: Includes a selection of modern medicines. Competitors include domestic and international pharmaceutical giants. Market Share data is not readily available.
Market Dynamics
Industry Overview
The TCM market in China is large and growing, driven by increased consumer interest in traditional remedies and government support. The overall pharmaceutical market is highly competitive.
Positioning
Universe Pharmaceuticals focuses on TCM products and seeks to differentiate through quality and brand recognition. However, it faces stiff competition from larger, more established players.
Total Addressable Market (TAM)
The TAM for pharmaceuticals and TCM in China is estimated to be in the hundreds of billions of USD. Universe Pharmaceuticals is positioned to capture a small portion of this market but faces challenges from bigger players and evolving regulations.
Upturn SWOT Analysis
Strengths
- Established TCM brand in certain regions of China
- Focus on traditional Chinese medicine
- Distribution network within China
- Development of TCM products
Weaknesses
- Limited international presence
- Heavy reliance on the Chinese market
- Smaller scale compared to major pharmaceutical companies
- Lack of publicly available market share data
Opportunities
- Expanding into new geographic regions within China
- Increasing exports of TCM products
- Developing innovative TCM-based products
- Partnerships with Western pharmaceutical companies
Threats
- Increasing competition from domestic and international players
- Changing regulatory landscape in China
- Fluctuations in raw material costs
- Potential for product liability claims
Competitors and Market Share
Key Competitors
- CRRXF
- SINOF
- CHAFF
- 999
Competitive Landscape
Universe Pharmaceuticals operates in a highly competitive market dominated by larger companies with greater resources and brand recognition. Its advantages hinge on specific TCM formulations and regional market penetration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not easily accessible and reliable.
Future Projections: Future projections are not readily available due to delisting and limited public information.
Recent Initiatives: Recent strategic initiatives are not publicly available.
Summary
Universe Pharmaceuticals Inc. operates within the large Chinese TCM market. It possesses regional brand recognition, but its growth is constrained by intense competition from larger firms and regulatory uncertainty. More up to date financial information is needed to establish a true picture of its health. Due to its delisting there are concerns about data collection and reliabilty.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Yahoo Finance
- Company Information
- Industry Reports
Disclaimers:
The information provided is based on limited publicly available data. Market share data and financial metrics are estimates and may not be precise. The AI-based rating is based on the information available, it is not a professional financial assessment. Not a recommendation to buy, sell or hold securities.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Universe Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-23 | CEO & Chairman Mr. Gang Lai | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 225 | |
Full time employees 225 | |||
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sells of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.